Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein ...

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores ...

Alan Alda says the first Parkinson’s symptom that he experienced ‘was not that well-known’ at the time, adding that he had ...

Alan Alda opened up about his Parkinson's disease — 11 years after he was first diagnosed.

Alan Alda has lived publicly with Parkinson’s disease for eight years, but at 90 he still refuses to let the diagnosis become ...

Alan Alda opens up about Parkinson’s disease in a new interview, sharing, ‘It’s not who I am.’ ...

Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...

Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced that four poster presentations will be featured at the 2026 International ...

A human-specific GLUD2 gene variant worsens Parkinson's disease pathology in mice by driving complement C3 signaling from astrocytes to microglia, revealing a potential therapeutic target.

Another potential blockbuster just joined AbbVie's drug portfolio.

Two devastating movement disorders, Parkinson’s disease and multiple system atrophy, often look so similar in the clinic that ...

During a house clearance in London in 2023, a remarkable discovery was made: rare desktop computers from 1972, namely the Q1 ...